Hmdb loader

HMDBP00699 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) Metabolite Associations

Displaying all 13 metabolite protein links
HMDB ID Name CAS NumberStructureFormula Average Mass
Monoisotopic Mass 		References
HMDB0000053Androstenedione63-05-8ThumbC19H26O2286.4085
286.193280076		Not Available
HMDB0000217NADP53-59-8ThumbC21H28N7O17P3743.405
743.075452041		Not Available
HMDB0000221NADPH53-57-6ThumbC21H30N7O17P3745.4209
745.091102105		Not Available
HMDB0000234Testosterone58-22-0ThumbC19H28O2288.4244
288.20893014		Not Available
HMDB0000899Androstanedione846-46-8ThumbC19H28O2288.4244
288.20893014		Not Available
HMDB0001984Finasteride98319-26-7ThumbC23H36N2O2372.5441
372.277678406		Not Available
HMDB00021977a,12a-Dihydroxy-cholestene-3-oneThumbC27H44O3416.6365
416.329045274		Not Available
HMDB0002833Testosterone sulfate651-45-6ThumbC19H28O5S368.488
368.165744696		Not Available
HMDB0002961Dihydrotestosterone521-18-6ThumbC19H30O2290.4403
290.224580204		Not Available
HMDB00038185-Androstenediol521-17-5ThumbC19H30O2290.4403
290.224580204		Not Available
HMDB00068867a,12a-Dihydroxy-5a-cholestan-3-oneThumbC27H46O3418.6523
418.344695338		Not Available
HMDB0014511Levonorgestrel797-63-7ThumbC21H28O2312.4458
312.20893014
  1. Hammond GL, Rabe T, Wagner JD: Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am J Obstet Gynecol. 2001 Aug;185(2 Suppl):S24-31. [PubMed:11521119 ]
  2. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S: Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000 Aug;14(4):223-30. [PubMed:11075290 ]
HMDB0015258Dutasteride164656-23-9ThumbC27H30F6N2O2528.5297
528.221147444
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. [PubMed:16818707 ]
  3. Rathnayake D, Sinclair R: Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304. doi: 10.1517/14656561003752730. [PubMed:20426708 ]
  4. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors. Steroids. 2010 Feb;75(2):109-53. doi: 10.1016/j.steroids.2009.10.005. Epub 2009 Oct 30. [PubMed:19879888 ]
  5. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263 ]
  6. Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. [PubMed:19543428 ]
  7. Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. [PubMed:18318566 ]
  8. Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. [PubMed:19200641 ]
  9. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16. [PubMed:19091347 ]
Displaying all 13 metabolite protein links